| Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates EE Walsh, RW Frenck Jr, AR Falsey, N Kitchin, J Absalon, A Gurtman, ... New England Journal of Medicine 383 (25), 2439-2450, 2020 | 2800 | 2020 |
| Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults MJ Mulligan, KE Lyke, N Kitchin, J Absalon, A Gurtman, S Lockhart, ... Nature 586 (7830), 589-593, 2020 | 1818 | 2020 |
| Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans TD Querec, RS Akondy, EK Lee, W Cao, HI Nakaya, D Teuwen, A Pirani, ... Nature immunology 10 (1), 116-125, 2009 | 1265 | 2009 |
| Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection J Wrammert, D Koutsonanos, GM Li, S Edupuganti, J Sui, M Morrissey, ... Journal of Experimental Medicine 208 (1), 181-193, 2011 | 942 | 2011 |
| Molecular signatures of antibody responses derived from a systems biology study of five human vaccines S Li, N Rouphael, S Duraisingham, S Romero-Steiner, S Presnell, ... Nature immunology 15 (2), 195-204, 2014 | 769 | 2014 |
| Efficacy trial of a DNA/rAd5 HIV-1 preventive vaccine SM Hammer, ME Sobieszczyk, H Janes, ST Karuna, MJ Mulligan, ... New England Journal of Medicine 369 (22), 2083-2092, 2013 | 721 | 2013 |
| Phase 3 safety and efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 vaccine AR Falsey, ME Sobieszczyk, I Hirsch, S Sproule, ML Robb, L Corey, ... New England Journal of Medicine 385 (25), 2348-2360, 2021 | 684 | 2021 |
| Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines JD Miller, RG van der Most, RS Akondy, JT Glidewell, S Albott, ... Immunity 28 (5), 710-722, 2008 | 677 | 2008 |
| Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus L Priyamvada, KM Quicke, WH Hudson, N Onlamoon, J Sewatanon, ... Proceedings of the National Academy of Sciences 113 (28), 7852-7857, 2016 | 651 | 2016 |
| Homologous and heterologous Covid-19 booster vaccinations RL Atmar, KE Lyke, ME Deming, LA Jackson, AR Branche, HM El Sahly, ... New England Journal of Medicine 386 (11), 1046-1057, 2022 | 547 | 2022 |
| Origin and differentiation of human memory CD8 T cells after vaccination RS Akondy, M Fitch, S Edupuganti, S Yang, HT Kissick, KW Li, ... Nature 552 (7685), 362-367, 2017 | 538 | 2017 |
| Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells GM Li, C Chiu, J Wrammert, M McCausland, SF Andrews, NY Zheng, ... Proceedings of the National Academy of Sciences 109 (23), 9047-9052, 2012 | 458 | 2012 |
| The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in nonhuman primates BE Jones, PL Brown-Augsburger, KS Corbett, K Westendorf, J Davies, ... Science translational medicine 13 (593), eabf1906, 2021 | 441 | 2021 |
| Magnitude of Functional CD8+ T-Cell Responses to the Gag Protein of Human Immunodeficiency Virus Type 1 Correlates Inversely with Viral Load in Plasma BH Edwards, A Bansal, S Sabbaj, J Bakari, MJ Mulligan, PA Goepfert Journal of virology 76 (5), 2298-2305, 2002 | 441 | 2002 |
| The safety, immunogenicity, and acceptability of inactivated influenza vaccine delivered by microneedle patch (TIV-MNP 2015): a randomised, partly blinded, placebo-controlled … NG Rouphael, M Paine, R Mosley, S Henry, DV McAllister, H Kalluri, ... The Lancet 390 (10095), 649-658, 2017 | 405 | 2017 |
| The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response RS Akondy, ND Monson, JD Miller, S Edupuganti, D Teuwen, H Wu, ... The Journal of Immunology 183 (12), 7919-7930, 2009 | 381 | 2009 |
| Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials C Axfors, AM Schmitt, P Janiaud, J Van’t Hooft, S Abd-Elsalam, EF Abdo, ... Nature communications 12 (1), 2349, 2021 | 368 | 2021 |
| Protection against vaginal SIV transmission with microencapsulated vaccine PA Marx, RW Compans, A Gettie, JK Staas, RM Gilley, MJ Mulligan, ... Science 260 (5112), 1323-1327, 1993 | 334 | 1993 |
| Safety, tolerability, and immunogenicity of two Zika virus DNA vaccine candidates in healthy adults: randomised, open-label, phase 1 clinical trials MR Gaudinski, KV Houser, KM Morabito, Z Hu, G Yamshchikov, ... The Lancet 391 (10120), 552-562, 2018 | 316 | 2018 |
| Systems analysis of immunity to influenza vaccination across multiple years and in diverse populations reveals shared molecular signatures HI Nakaya, T Hagan, SS Duraisingham, EK Lee, M Kwissa, N Rouphael, ... Immunity 43 (6), 1186-1198, 2015 | 316 | 2015 |
